Sexual Health and Reproductive Research
Compounds studied for central arousal signaling, GnRH axis regulation, and reproductive neuroendocrinology
Sexual health and reproductive research examines the neuroendocrine pathways governing sexual behavior, arousal, and reproductive hormone regulation. Two distinct but complementary axes are represented in this use case: the melanocortin system, which controls central arousal and sexual behavior through MC3R and MC4R receptor signaling, and the kisspeptin-GnRH axis, which serves as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis controlling gonadotropin release and gonadal steroid production. Researchers studying reproductive biology, fertility disorders, or sexual behavior paradigms draw on both axes to construct comprehensive models of the regulatory systems governing reproductive physiology.
Compounds in This Use Case
Each compound contributes a distinct mechanism relevant to this research objective.
PT-141
$139Role
Melanocortin receptor agonist studied for central arousal and sexual behavior signaling via MC3R and MC4R in preclinical and clinical models.
Mechanism
Acts as a cyclic heptapeptide agonist of MC3R and MC4R receptors in hypothalamic and limbic regions, activating dopaminergic pathways associated with sexual arousal and behavior, with an FDA-approved nasal formulation (Vyleesi) for HSDD in premenopausal women.
Kisspeptin
$149Role
GPR54 ligand studied as the primary upstream regulator of the GnRH pulse generator and the hypothalamic-pituitary-gonadal axis.
Mechanism
Activates GPR54 on hypothalamic GnRH neurons to drive GnRH pulse generation and downstream LH and FSH release, serving as the master gatekeeper of the entire gonadotropin axis, with human clinical trial data in hypothalamic amenorrhea and male hypogonadotropic hypogonadism.
Research Context
PT-141 and Kisspeptin represent the two most mechanistically distinct research tools for studying the behavioral and endocrine dimensions of reproductive biology. PT-141 (Bremelanotide) has FDA approval as Vyleesi for hypoactive sexual desire disorder, providing a regulatory anchor for melanocortin sexual research. Kisspeptin was identified as a reproductive regulator following the 2003 NEJM paper by Seminara et al. linking GPR54 loss-of-function mutations to idiopathic hypogonadotropic hypogonadism, which established it as the gatekeeper of puberty and fertility. Human clinical research from Dhillo, Jayasena, and colleagues in the UK has further characterized its therapeutic potential.
Related Compound Comparisons
Explore side-by-side mechanism comparisons for the compounds in this use case.
Frequently Asked Questions
Source These Compounds
All compounds in this use case are available from Spartan Peptides at least 98% HPLC-verified purity. Domestic US supply with same-day dispatch before 2 PM. For in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.